Paul D B, Kruse C A
Department of Immunology, University of Colorado Health Sciences Center, 4200 E. Ninth Avenue, Denver, CO 80262, USA.
Curr Neurol Neurosci Rep. 2001 May;1(3):238-44. doi: 10.1007/s11910-001-0024-8.
Malignant brain tumors are notoriously invasive. Although surgical debulking can relieve the patient of the main mass of tumor, adjuvant treatments are needed to target the glioma cells that infiltrate through normal parenchyma as single cells or pockets of tumor cells from which recurrent tumors arise. Successful adjuvant cellular therapy of brain tumors, or activation of endogenous immune cells, requires that either cell effectors make direct contact with tumor cells or come within close proximity to them and exert an indirect effect. This review examines current clinical trials aimed at direct lysis of glioma cells and trials making gliomas more visible to the endogenous immune system.
恶性脑肿瘤具有极强的侵袭性。尽管手术切除肿瘤主体可使患者病情得到缓解，但仍需辅助治疗来靶向那些以单细胞形式或肿瘤细胞簇形式浸润正常实质组织并引发复发性肿瘤的胶质瘤细胞。成功的脑肿瘤辅助细胞治疗或激活内源性免疫细胞，要求细胞效应器要么直接与肿瘤细胞接触，要么与肿瘤细胞紧密相邻并发挥间接作用。本文综述了旨在直接裂解胶质瘤细胞的当前临床试验，以及使胶质瘤对内源性免疫系统更易见的试验。
